What is done in Phase 5 of drug development?

• A. Large-scale Phase 3 efficacy trials.
• B. Additional clinical studies in special populations or for a new indication; not all drugs undergo this phase.
• C. Post-marketing surveillance after approval.
• D. Manufacturing scale-up.

Answer: (B)

In this framework, Phase 5 is about conducting extra clinical studies after a drug has been approved, aimed at expanding knowledge about its use. These studies look at special populations (like children, elderly, or patients with certain comorbidities) or explore a new indication for the drug. The goal is to confirm safety and effectiveness in real-world settings and to support labeling changes or broader use. Not every drug will have Phase 5—the need depends on regulatory requirements, existing data, and risk–benefit considerations.

Large-scale efficacy trials are done earlier (in Phase 3) to establish how well the drug works before approval. Manufacturing scale-up happens during development and early production activities, not as Phase 5. Post-marketing surveillance after approval is often described separately as ongoing safety monitoring, which some curricula call Phase 4.